Search Results

VX-222 50mg 50mg  | Purity Not Available

Adooq Bioscience

VX-222 is a small molecule non-nucleoside inhibitor of HCV NS5B polymerase that is being investigated for the treatment of hepatitis C virus infection.

More Information Supplier Page

VX-222 5mg 5mg  | Purity Not Available

Adooq Bioscience

VX-222 is a small molecule non-nucleoside inhibitor of HCV NS5B polymerase that is being investigated for the treatment of hepatitis C virus infection.

More Information Supplier Page

VX-222 10mM * 1mL in DMSO 10mM * 1mL in DMSO  | Purity Not Available

Adooq Bioscience

VX-222 is a small molecule non-nucleoside inhibitor of HCV NS5B polymerase that is being investigated for the treatment of hepatitis C virus infection.

More Information Supplier Page

Vicriviroc Malate 50mg 50mg  | Purity Not Available

Adooq Bioscience

Vicriviroc Malate is a second generation orally active CCR5 antagonist, which is also a potent inhibitor of HIV-1 entry into target cells, with a mean IC50 =0.46 nM and IC50 =1~10 nM to HIV isolates (n=52).

More Information Supplier Page

Vicriviroc Malate 5mg 5mg  | Purity Not Available

Adooq Bioscience

Vicriviroc Malate is a second generation orally active CCR5 antagonist, which is also a potent inhibitor of HIV-1 entry into target cells, with a mean IC50 =0.46 nM and IC50 =1~10 nM to HIV isolates (n=52).

More Information Supplier Page

Vicriviroc Malate 100mg 100mg  | Purity Not Available

Adooq Bioscience

Vicriviroc Malate is a second generation orally active CCR5 antagonist, which is also a potent inhibitor of HIV-1 entry into target cells, with a mean IC50 =0.46 nM and IC50 =1~10 nM to HIV isolates (n=52).

More Information Supplier Page

Vicriviroc Malate 10mg 10mg  | Purity Not Available

Adooq Bioscience

Vicriviroc Malate is a second generation orally active CCR5 antagonist, which is also a potent inhibitor of HIV-1 entry into target cells, with a mean IC50 =0.46 nM and IC50 =1~10 nM to HIV isolates (n=52).

More Information Supplier Page